FISHing for the Miracle of Eicosapentaenoic Acid.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

34 citing papers in PubMed.

1. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.Circulation · 2021 · on this map
   Trial
2. Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers.Journal of the American Heart Association · 2020
   Trial
3. Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence.Circulation research · 2020
   Trial
4. Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.Cardiovascular diabetology · 2026
   Review
5. Plasma fatty acid profiles and coronary artery disease burden assessed by coronary CT angiography: an observational study.Scientific reports · 2026
   Observational
6. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids.Cardiovascular drugs and therapy · 2025
   Review
7. Modern therapy of patients with lupus erythematosus must include appropriate management of their heightened rates of atherosclerotic cardiovascular events: a literature update.Lupus science & medicine · 2025
   Review
8. EPA Induces an Anti-Inflammatory Transcriptome in T Cells, Implicating a Triglyceride-Independent Pathway in Cardiovascular Risk Reduction.JACC. Basic to translational science · 2025
   Article
9. Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
10. Eicosapentaenoic Acid: between Cardiovascular Benefits and the Risk of Atrial Fibrillation.Endocrine, metabolic & immune disorders drug targets · 2024
    Article
11. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Review
12. Update of the risk assessment of mineral oil hydrocarbons in food.EFSA journal. European Food Safety Authority · 2023
    Article
13. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.Cardiovascular drugs and therapy · 2023
    Article
14. Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.Cardiovascular research · 2023
    Review
15. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.Clinical drug investigation · 2022
    Article
16. New therapeutic approaches for the treatment of hypertriglyceridemia.Herz · 2022
    Review
17. Differentiating EPA from EPA/DHA in cardiovascular risk reduction.American heart journal plus : cardiology research and practice · 2022
    Review
18. Addressing dyslipidemic risk beyond LDL-cholesterol.The Journal of clinical investigation · 2022
    Review
19. Working towards full eradication of lipid-driven cardiovascular risk?Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2022
    Review
20. The challenge of choosing in cardiovascular risk management.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2022
    Review

Corrections and comments

• Comment on
  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.2019

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as